Ropes & Gray Represents TRexBio in Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies for Immune-Mediated Diseases
Ropes & Gray represented TRexBio in a multi-year research collaboration and exclusive worldwide license agreement with Eli Lilly and Company to develop novel therapies for the treatment of immune-mediated diseases. The collaboration and license agreement was announced on January 9th.
TRexBio’s Deep Biology platform combines high-resolution sequencing of human tissue, cutting-edge computational biology tools, and scalable translational biology assay systems into an optimized workflow with a focus on Treg behavior in human tissue. The Deep Biology platform maps human tissue Treg behavior to disease processes, enabling efficient discovery and functional characterization of unique targets and rapid advancement of therapeutic candidates focused on Treg biology.
Under the agreement, TRexBio receives an upfront payment of $55 million and is eligible to receive more than $1.1 billion on achievement of certain development, regulatory, and commercial milestones. TRexBio is also entitled to receive tiered royalties on product sales. In exchange, Lilly will be granted an exclusive worldwide license to develop and commercialize drug candidates from three programs.
The Ropes & Gray team was led by IP transactions partner Abigail Gregor and IP transactions associate Ian Nilsen.